Dextromethorphan ( think cough syrup) for OCD: A Promising Glutamate-Targeted Augmentation Strategy?

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Unfollow podcast failed

Dextromethorphan ( think cough syrup) for OCD: A Promising Glutamate-Targeted Augmentation Strategy?

Listen for free

View show details

A small 2026 randomized controlled trial found that adding low-dose dextromethorphan (DXM, 15 mg twice daily) to ongoing SSRI treatment significantly reduced Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores in adults with SSRI-resistant OCD, dropping from about 26.6 to 16.3 over 12 weeks versus little change on placebo. Strengths include its double-blind, placebo-controlled design, strong statistical effect size, excellent tolerability with no reported side effects, and alignment with the glutamatergic hypothesis of OCD. Limitations center on the tiny sample size (n=40), single-center location in Iran, lack of secondary outcomes or long-term follow-up, and potential pharmacokinetic variability from SSRI interactions; broader evidence from meta-analyses of other glutamatergic agents supports the approach but calls for larger confirmatory trials.

No reviews yet